Members in attendance
- Director of Data Management and Transformation (Chair), NHS England
- Director of Digital Operations and Innovation, NHS England
- Head of Information Governance, Federated Data Platform (FDP)
- Director of Advanced Analysis, Data and Analytics, NHS England
- Director of Delivery, External Supplier
- Assistant Director, Data Governance and Assurance, NHS England
- Deputy Director, Product Development and Implementation NHS England
- Regional Director of Digital Transformation – East of England
- Chief Medical Officer, Kent and Medway NHS Trust
- Director of Urgent and Emergency Care (UEC) Delivery, NHS England
- Regional Director of Digital Transformation – Midlands, NHS England
- Director of Privacy, Transparency and Ethics, NHS England
- Executive Director, Strategy Change and In-Hospital Services, NHS England
- Regional Chief Operating Officer – Midlands, NHS England
- Senior Governance Secretariat Officer, FDP, NHS England
- Corporate and Governance Compliance Manager, FDP, NHS England
- Portfolio Director, FDP, NHS England
- Programme Director, FDP, NHS England
- Deputy Director of Demand, FDP, NHS England
- Assistant Director of Integration and Assurance, NHS England
- Deputy Director, FDP, NHS England
Apologies
- Director of Elective Recovery, NHS England
- Joint Chief Digital Officer, NHS England
- Director of Data and Analytics/Deputy Chief Digital Information Officer, NHS England
- Assistant Head of Communications, NHS England
- Principal Accountant, NHS England
- Deputy Director, Demand and Delivery, NHS England
- Director of Transformation and Quality Improvement, NHS England
- Medical Productivity Director, NHS England
- Director – Data and Analytics, Transformation Director of Out of Hospital – Urgent and Emergency Care, NHS England
- Deputy Managing Director, NHS England
- Programme Management Director, NHS England
- Director, National Health and Social Care Discharge Taskforce, NHS England
- Finance Partnering Senior Lead, NHS England
- Director of Privacy, Transparency and Ethics, NHS England
- Chief Technology Officer, NHS England
- Senior Commercial Lead, External Supplier
- Director of Delivery – National Cancer Programme, NHS England
- Deputy Director of Transforming Operational Delivery, NHS England
- National Medical Director for Secondary Care, NHS England
- Deputy Director of Data Engineering, NHS England
- Commercial Director, External Supplier
1. Welcome, introductions and declarations of interest
The Chair opened the meeting.
Apologies for absence were noted.
There were no declarations of interest.
2. Review of minutes and actions
The minutes from the meeting held on 4 December 2025 were reviewed and approved.
The Board noted that all actions had been completed. A previously scheduled product demonstration will be delivered at a forthcoming Regional Digital Forum.
3. Decisions made
The Chair provided a summary of the recent Programme Delivery Group (PDG) decisions.
The Board noted the progression of the Strategic commissioning tool (SCT) into general availability (GA).
Action (product): Bring a SCT demo to a future Programme Board meeting.
4. Highlights, FDP in numbers and risks
The Chair presented the FDP highlight report and provided an overview of programme progress.
The Board noted continued delivery progress across multiple products and the programme’s focus on strengthening delivery capacity and resilience in the context of wider organisational change.
The Board noted the appointment of a national clinical executive sponsor to provide strengthened clinical leadership and oversight.
An update was provided on pathway development activity, including screening pathways delivered in collaboration with national programmes. The Board noted the growing role of the FDP in supporting pathway visibility, integration, and workflow optimisation.
Action (product): A summary of the relevant pathway use case and solution approach will be circulated, with a demonstration to be scheduled at a future meeting.
The Board received an update on programme key performance indicators (December 2025 data).
An update was provided regarding national and regional evaluation activity. The Board noted that a national evaluation partner will work alongside local teams to assess product impact and value for money.
The Board reviewed high-level programme risks, including workforce capacity, delivery dependencies and organisational transition. It was acknowledged that the coming months would be important in confirming delivery arrangements and ensuring clarity of roles and responsibilities across national and regional teams.
Action (Programme Management Office): A dedicated session will be scheduled with regional colleagues to review the operating model, align expectations and confirm delivery responsibilities.
The Board received the January 2026 “FDP in numbers” update and noted continued evidence of impact across provider organisations.
5. Demand and Delivery Update
The Board received an update on Demand and Delivery activity across acute, mental health and community providers.
Progress against programme targets, engagement activity, and risk management were noted.
Board members were asked to continue supporting regional engagement conversations where appropriate.
The Board noted the update.
6. Product update
The Board received an update on product development and delivery.
A demonstration was provided of the Demand Centre product, outlining its role in consolidating provider demand, supporting clinical decision-making, and enabling workflow automation. It was reiterated that the tool functions as decision support, with clinicians remaining fully responsible for care decisions.
The importance of clinician and patient co-design was emphasised to ensure tools support equitable access and do not create unintended barriers.
Action (product): Further architectural documentation will be shared to provide clarity on how FDP products integrate with existing systems and infrastructure.
The Board noted ongoing work to enhance patient visibility of referral status via national digital channels.
The Board received and noted the product update.
7. Solution Exchange update
The Board received an update on Solution Exchange (SolEx), including its objectives, supplier onboarding approach, technical standards and commercial considerations.
Discussion focused on fair use and cost allocation principles for national and local FDP usage. The Board noted that an existing Fair use policy is in place and that a revised consumption policy is planned for April 2026 to provide further clarity on usage thresholds and cost expectations.
Action (Programme Management Office): Share the current Fair use policy and associated consumption guidance.
Action (Programme Management Office): Arrange a follow-up discussion to clarify technical and procurement framework considerations relating to third-party products.
The Board emphasised the importance of transparency regarding national versus local funding responsibilities and the development of a consistent procurement approach for FDP-compatible third-party products.
The Board noted that further work is underway in this area.
8. Any other business and close
No additional items were raised and the meeting concluded.
Date of next meeting: Thursday 26 February 2026
Completed by Programme Secretariat
Reviewed by Senior Responsible Officer
Confirmed by Chair